NCT00228176View on ClinicalTrials.gov

Atherosclerosis Underlying Development Assessed by Intima-Media Thickness in Patients on Rimonabant

PHASE3TerminatedINTERVENTIONAL
Enrollment

661

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions
Carotid Artery PlaqueArteriosclerosisObesityMetabolic Syndrome X
Interventions
DRUG

Rimonabant

Tablet, oral administration

DRUG

Placebo (for Rimonabant)

Tablet, oral administration

Trial Locations (6)

08807

Sanofi-Aventis Administrative Office, Bridgewater

Unknown

Sanofi-Aventis Administrative Office, Laval

Sanofi-Aventis Administrative Office, Paris

Sanofi-Aventis Administrative Office, Gouda

Sanofi-Aventis Administrative Office, Barcelona

Sanofi-Aventis Administrative Office, Guildford Surrey

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY